Trials / Active Not Recruiting
Active Not RecruitingNCT04754191
Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2 Umbrella Protocol of Enfortumab Vedotin as Monotherapy and Combined With Other Agents in Patients With Metastatic Castration-Resistant Prostate Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- University of Utah · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, phase II umbrella trial assessing the anti-tumor activity of enfortumab alone and in combination with other anti-cancer agents in subjects with metastatic castration-resistant prostate cancer. The trial will open to enrollment in Cohort A, enfortumab monotherapy. Additional cohorts may be added as new drug combinations are identified.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enfortumab vedotin | Cohort A will be treated with enfortumab vedotin on a 28 day cycle for up to 12 months. |
Timeline
- Start date
- 2022-06-05
- Primary completion
- 2025-04-22
- Completion
- 2027-01-01
- First posted
- 2021-02-15
- Last updated
- 2026-02-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04754191. Inclusion in this directory is not an endorsement.